IMPACT CHINA: Pharmaceutical R&D Global Summit
Sept 18-21, 2005, Shanghai, China
Discount for SAPA Members
Strategic Research Institute is pleased to offer a 30% discount on the conference registration fees for SAPA members (only applicable for people that currently have not registered). To register for the conference through the SAPA discount, you must contact the event director Jon E. Liong at jliong@srinstitute.com or 212-967-0095, ext. 243.
www.srinstitute.com/china
IMPACT CHINA: Pharmaceutical R&D Global
Summit
SUNDAY, SEPTEMBER 18, 2005
(4:00-7:00pm)
Pre-Conference
Workshops
WORKSHOP #1
Intellectual
Property Portfolio Management
WORKSHOP #2
Preclinical
Requirements for the Start of Clinical Trials in China and the US
(7:00-8:30pm)
Welcome to Shanghai
Reception
MONDAY, SEPTEMBER 19, 2005
CHINA’S
ROLE IN THE GLOBAL PHARMACEUTICAL MARKETPLACE
(8:15am-12:30pm)
Biotech State of Industry
G. Steven Burrill
Chief
Executive Officer, Burrill & Co.
The Competitiveness of China – A Global Context
Bev Salt, Ph.D.
Vice President, International Planning, AstraZeneca
Speeding Up Drug Discovery & Development
through China-Based Operations
Andreas
Tschirky, Ph.D.
General Manager, Roche R&D China
The Role of China & India in Research
Outsourcing & Alliances
Steven Hutchins,
Ph.D.
Director, Outsourcing, Merck & Co.
A Global Comparison of
Emerging Markets: China vs. India
Moderator:
Lorenz Ng, M.D., Ph.D.
VP, Research Alliance &
Business Development, Asia Pacific, Eli
Lilly Asia
Panelists:
Sandesh Seth, M.S., M.B.A.
Managing Director, AmerAsia Capital Partners
Ravi Sodha, Ph.D.
Head, Business Development, Novartis Pharmaceuticals
Steven Hutchins, Ph.D.
Director, Outsourcing, Merck & Co.
Bev Salt, Ph.D.
Vice President, International
Planning, AstraZeneca
INTELLECTUAL
PROPERTY RIGHTS IN CHINA
(1:45-3:30pm)
Intellectual Property
Landscape & Strategies in China- Lessons from the Past
Moderator:
Michael Wise, J.D.
Partner, Perkins Coie
Panelists:
Jinyan Cao
Deputy Director General, IP
Development Research Center, SIPO
James Green
Government Relations Manager, The American Chamber of Commerce Shanghai
Tony Quan
President, Beijing Institute of Intellectual Property Strategy
Siegmund Gutman, Ph.D.
Senior Counsel/Patent Counsel, Amgen
OUTSOURCING TO CHINA
(4:00-6:00pm)
Outsourcing Preclinical
Development to China
Moderator:
Ada Kung, Ph.D.
Vice President, Product
Development, Bridge Pharmaceuticals
Panelists:
Lorenz Ng, M.D., Ph.D.
VP, Research Alliance &
Business Development, Asia Pacific,Eli
Lilly Asia
Michael Hui, Ph.D.
Chief Executive Officer, Shanghai ChemPartner
Kewen Jin, Ph.D.
Chief Executive Officer, BioExplorer
Outsourcing Clinical Drug Development to China
Mark Engel
Chief Executive Officer, Excel Pharmastudies
TUESDAY, SEPTEMBER 20, 2005
CONDUCTING
CLINICAL TRIALS IN CHINA
(8:15am-5:05pm)
The Current Drug
Registration Process in China
Cao Wenzhuang, Ph.D.
(invited)
Director, Department of Drug
Registration
State Food & Drug Administration, China
(SFDA)
COMMIT- A Case Study on a 46,000 Patient
Clinical Trial in China
Zhengming Chen,
M.D., Ph.D.
Principal Investigator for COMMIT,
Oxford University
Planning Global/Regional Clinical Studies
Ruiping Dong, M.D.,
Ph.D.
Vice President, Research &
Development, Bristol-Myers Squibb Japan
SFDA vs. FDA: Similarities, Differences, &
Harmonization
Ada Kung, Ph.D.
Vice President, Product
Development, Bridge Pharmaceuticals
Planning &
Management of Global Clinical Trials with Enrollment in China: Challenges,
Opportunities, and Operational/Regulatory Considerations
Discussion Leader:
Dan Zhang, M.D., M.P.H.
Head, Clinical
Development & Safety, Sigma-Tau
Research
Panelists:
Ling Su, M.D.
Medical
& International Pharma Development Director, Roche R&D Shanghai
Ruiping Dong, Ph.D.
Vice President, Research &
Development, Bristol-Myers Squibb Japan
Zhengming Chen, M.D., Ph.D.
Principal Investigator, Oxford University
Cao Wenzhuang, Ph.D. (invited)
Director, Department of Drug
Registration
State Food & Drug Administration, China (SFDA)
Clinical Use of
Imatinib in China
Fangping Chen, M.D.
Chair, Department of Hematology, Xiang-Ya Hospital/Xiang-Ya Medical School
Clinical Investigations of Anti-HBV Drug
Development in China
G.B. Yao, M.D.
Professor, Shanghai Jing-An Qu Central Hospital
Logistics Handling of Clinical Trial Materials
Eric von Zwisler
Chief Executive Officer, Zuellig Pharma China
Leveraging Information Technology for
Clinical Trials in China
Man-Cheong Fung,
M.B.A., Ph.D.
Head, Clinical Development-
Specialty Pharma Products, JNJ-McNeil
Consumer & Specialty Products
Benefits of Using a Central Laboratory in Asia
Linda Yare
Director,
Asia Operations, CentraLabs Clinical
Research
Clinical Data & Statistical Analysis
through a Biometrics Center in China for Global Clinical Trials
Munish
Mehra, Ph.D.
Chief Information
Officer, Medifacts International
Jillian
Lin
Director of Asian
Operations, Medifacts International
WEDNESDAY, SEPTEMBER 21, 2005
THE
EMERGING R&D LANDSCAPE IN CHINA
(8:05-9:35am)
A New Perspective of Drug Discovery in China
Li Chen, Ph.D.
Head of Research, Roche R&D China
Building the Translational Highway from Bench
to Clinic in China
Ling Chen, M.D.,
Ph.D.
Director General & Professor, Guangzhou Institute of Biomedicine and
Health
Current cGMP Status & Future Outlook in China
Wang Zhexiong, Ph.D. (invited)
Vice
Director, Safety Supervision Division
State Food & Drug
Administration (SFDA)
INVESTMENT
& PARTNERING IN CHINA’S
BIOPHARMACEUTICAL
INDUSTRY
(10:05am-3:40pm)
How to Build a Life
Sciences Bridge: Investment Opportunities & Challenges in China’s
Biopharmaceutical Industry
Discussion Leader:
Jonathan Wang, Ph.D.
General Manager, China, Burrill & Company
Panelists:
Frank Kung, Ph.D.
Managing Director, Vivo Ventures
Alan S. Paau, M.B.A., Ph.D.
Assistant Vice Chancellor, University of California at San Diego
Mario Gobbo
Head, Life Sciences, International Finance Corporation- World
Bank
Kenneth Fong
President, Kenson Ventures
Bioentrepreneurship: Can the US Biotech Model
be Adapted to US-Asia (China-India) Cross Border Ventures? The $500 Million
Question.
Sandesh Seth, M.S., M.B.A.
Managing Director, AmerAsia Capital Partners
Trans-Pacific Technology Transfer: A Look at
the Past and the Roles of US Universities
Alan S. Paau,
M.B.A., Ph.D.
Assistant Vice Chancellor, University of California at San Diego
Accelerating Development of Novel
Therapeutics in China through Licensing and Co-Development Strategies
Sam Lou, M.B.A.
Chief Operating Officer, Crimson Pharmaceutical
East/West
Pharmaceutical Licensing & Partnerships: What the Future Holds
Moderator:
James Foley, Ph.D.
Vice President, Business
Development, Bristol-Myers Squibb- Japan
Panelists:
Peter T. S. Huang
President & CEO, BioPro Pharmaceutical Co.
Ling Chen, M.D., Ph.D.
Director General & Professor, Guangzhou Institute of Biomedicine and
Health
James Zhu, Ph.D.
Associate Director, Perkins Coie
Achieving Commercial
Success in the Chinese Market
Raymond Hill
Vice President, Asia-Pacific
Consulting & Services, IMS Health
Conference Concludes
Discount for SAPA
Members
Strategic Research Institute is
pleased to offer a discount on the conference registration fees for SAPA
Members. To register for the conference
through the SAPA discount, you must contact the event director Jon E. Liong at jliong@srinstitute.com or 212-967-0095,
ext. 243.
Please visit the
conference website at www.srinstitute.com/china for the complete full agenda and details of IMPACT CHINA.
